Figure 3 | British Journal of Cancer

Figure 3

From: A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma

Figure 3

CT scans of the patient who showed sustained PR during the trial: At baseline (A), day 84 (B), 12 (C) and 36 (D) months post-treatment. Resolution of one liver metastasis is evident by day 84 with significant ablation of the second, which also eventually resolves. The patient is a long-term survivor at ++36 months and considered in full remission.

Back to article page